Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 17, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

[Towards a histologically guided management for NSCLC].

G Milano1, J Bennouna, D Planchard

  • 1Laboratoire d'Oncopharmacologie, Centre Antoine Lacassagne, Nice, France. gerard.milano@cal.nice.fnclcc.fr

Revue Des Maladies Respiratoires
|December 25, 2009
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sex-based differences in tolerability of developmental antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC).

ESMO open·2026
Same author

Lung cancer brain metastases management at the dawn of personalized medicine: are we ready to break the barriers?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Encorafenib plus binimetinib versus dabrafenib plus trametinib for the first-line treatment of patients with BRAF<sup>V600E</sup>-mutant metastatic non-small cell lung cancer: a matching-adjusted indirect treatment comparison.

ESMO open·2026
Same author

Global advances and future directions in lung cancer care: expert consensus and strategic priorities.

ESMO open·2026
Same author

Next-generation multicenter studies: using artificial intelligence to automatically process unstructured health records of patients with lung cancer across multiple institutions.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Personalized treatment for non-small cell lung cancer (NSCLC) is evolving. Tailoring first-line chemotherapy based on histology and predictive markers improves patient outcomes and treatment tolerance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Anatomical Pathology

Context:

  • Current first-line chemotherapy for non-small cell lung cancer (NSCLC) is primarily histology-dependent.
  • Advancements in anatomical pathology and molecular biology are transforming cancer management.
  • The rapid development of novel therapeutic agents necessitates updated treatment selection strategies.

Purpose:

  • To highlight the need for integrating advanced diagnostic tools in NSCLC treatment selection.
  • To emphasize the shift from histology-based to personalized treatment approaches.
  • To advocate for patient stratification based on predictive biomarkers for chemotherapy efficacy and tolerance.

Summary:

  • The management of non-small cell lung cancer (NSCLC) requires a move beyond histology-based chemotherapy selection.

More Related Videos

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Related Experiment Videos

Last Updated: Jun 17, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

  • Integrating insights from morbid anatomy and molecular biology is crucial for identifying predictive criteria.
  • This allows for the definition of tailored treatment strategies, optimizing both efficacy and patient tolerance.

    • Impact:

    • Facilitates the development of precision medicine in NSCLC treatment.
    • Improves patient selection for first-line chemotherapy, enhancing treatment effectiveness.
    • Reduces treatment-related toxicity by predicting patient response and tolerance to chemotherapy.